



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website : www.fermentabiotech.com



May 26, 2026

Corporate Relations
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Dear Sir,

Sub: Intimation under Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 30 and other applicable provisions of Listing Regulations, we wish to inform you about the following decisions taken at the meeting of the Nomination and Remuneration Committee (Compensation Committee) and/or the Board of Directors held today i.e. Tuesday, May 26, 2026:

- (i) The Board of Directors, pursuant to provisions of Section 152 of the Companies Act, 2013, approved re-appointment of Ms. Rajeshwari Datla (DIN – 00046864) as a Non-executive Director of the Company, who is liable to retire by rotation at the ensuing 74th Annual General Meeting (AGM) and, being eligible, has offered herself for re-appointment, subject to the approval of members of the Company. The Board, pursuant to regulation 17(1A) and other applicable provisions of Listing Regulations, also approved continuation of Ms. Rajeshwari Datla (DIN: 00046864) as a Non-Executive Director on the Board of Directors of the Company who has attained Seventy Five (75) years of her age (currently, 76 years), subject to the approval of members of the Company.

The relevant details pertaining to the above, as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, January 30, 2026, are enclosed as **Annexure 1**.

- (ii) The Compensation Committee approved grant of 3,95,400 stock options to eligible employees under Fermenta Biotech Limited Employee Stock Option Scheme 2025 ('FBL ESOP 2025') read with applicable provisions of the SEBI (Share Based Employee Benefits) Regulation 2021.

The relevant details pertaining to the above, as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, January 30, 2026, are enclosed as **Annexure 2**.



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website : www.fermentabiotech.com



- (iii) The Board of Directors accorded its approval to make an application to National Stock Exchange of India Limited for seeking listing and trading of the Company's equity shares on NSE's platform through a direct listing route.
- (iv) The Board of Directors granted in-principle approval to Fermenta Environment Solutions Private Limited ('FESPL'), a wholly-owned subsidiary of the Company, to consider proposal for private placement of equity shares subject to necessary approvals. Upon successful implementation of private placement and allotment of shares to investor(s) thereunder, FESPL will cease to be a wholly-owned subsidiary of the Company.
- (v) The Board of Directors granted in-principle approval to FESPL for implementing Fermenta Environment Solutions Private Limited - Employee Stock Option Plan 2026 for grant of stock options *inter alia* to FESPL's employees including employees of holding company pursuant to applicable statutory provisions.

Kindly take the above on record.

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

Varadvinayak Khambete

Company Secretary & Head - Legal

Membership No. A33861

Encl: As above

Annexure 1 : Appointment / re-appointment of directors

Sr. No.	Particulars	Ms. Rajeshwari Datla
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment as a Non - Executive Director
2	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment	Re-appointment of Ms. Rajeshwari Datla (DIN – 00046864) as a Non-executive Director of the Company, who is liable to retire by rotation at the ensuing 74 th Annual General Meeting (AGM) and, being eligible, has offered herself for re-appointment at the AGM.
3	Brief profile (in case of appointment)	<p>Ms. Datla is a Bachelor of Science and has around five decades of rich experience in management and operations in the pharmaceutical industry.</p> <p>She has been associated with the Company as a non-executive director since 2005. At present, she is also a member of the Nomination and Remuneration Committee and the Corporate Social Responsibility Committee of the Company. With her invaluable contribution in the strategic and decision-making process, she has been instrumental in Company's operations and growth.</p>
4	Disclosure of relationships between directors (in case of appointment of a director).	Ms. Rajeshwari Datla is mother of Ms. Anupama Datla Desai, Executive Director, and Mr. Krishna Datla, Executive-Vice Chairman.

Annexure 2 : Grant of options under FBL ESOP 2025

Sr.	Particulars	Details
a)	Brief details of Options granted	3,95,400 (Three Lakh Ninety Five Thousand and Four Hundred) options have been granted to eligible employees as per FBL ESOP 2025.
b)	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (if applicable)	Yes.
c)	Total number of shares covered by these options	3,95,400 (Three Lakh Ninety Five Thousand and Four Hundred) equity shares of Rs. 5 each wherein each stock option is convertible into 1 (one) equity share.
d)	Pricing formula	Exercise price is determined at Rs. 83.67 per option.
e)	Options vested	Not Applicable.
f)	Time within which Options may be exercised	The Exercise Period for Vested Options shall be a maximum of 3 (Three) years commencing from the date of each Vesting.
g)	Options exercised	Not Applicable.
h)	Money realized by exercise of Options	Not Applicable.
i)	Total number of shares arising as a result of exercise of Option	Not Applicable.
j)	Options lapsed	Not Applicable.
k)	Variation of terms of Options	Not Applicable.
l)	Brief details of significant terms	Options granted shall have a vesting period of minimum 1 (One) year from the date of grant and all Options granted shall vest as per the Vesting schedule specified in the grant letter.
m)	Subsequent changes or cancellation or exercise of such Options	Not Applicable.
n)	Diluted earnings per share pursuant to issue of equity shares on exercise of Options.	Not Applicable.